Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 516 participants.

Also called NCT05141305

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 516 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05141305
Other papers using this trial's data
  • Clinical benefit of tenecteplase despite failed recanalization in late-window ischemic stroke: a post hoc analysis of the TRACE-3 trial BMC medicine, 2026-04-16 DOI, PubMed 41992212, PMC13202816 In the PMC Open Access subset under CC BY-NC-ND.
  • Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy The New England journal of medicine, 2024-07-18 DOI, PubMed 38884324

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05141305. Randomized; single masking; primary purpose treatment. Start 2022-01-19 (actual); primary completion 2024-01-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-III
Acronym
TRACE III
Condition
Ischemic Stroke, Acute
Intervention (Drug)
tenecteplase (0.25 mg/kg, Max 25 mg)
Intervention (Drug)
standard medical treatment
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct05141305
Content hash
0e91bc5683a329424b112826502725fcf8adc7fe82a1432af4795b4385252c79